Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | PAK3 | O75914 | 1/20 | 0.39 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12302876 | 0.95 | TRPV1 (0.40) | CCR2KCNH2PAK1TRPV1KIT | |
| SCHEMBL2385128 | 0.90 | PAK1 (0.43) | PAK1TRPV1KITPAK3PAK2 | |
| SCHEMBL2384156 | 0.84 | TRPV1 (0.43) | PAK1TRPV1KITPAK3PAK2 | |
| SCHEMBL2384579 | 0.84 | IDH2 (0.44) | PAK1TRPV1HTT | |
| SCHEMBL12302305 | 0.79 | TRPV1 (0.42) | PAK1TRPV1KITNR2E1LMNA | |
| SCHEMBL2382791 | 0.79 | TRPV1 (0.43) | TRPV1KITGAACNR2LMNA | |
| SCHEMBL2382905 | 0.79 | TRPV1 (0.46) | PAK1TRPV1KITGAANR2E1 | |
| SCHEMBL2382932 | 0.77 | TRPV1 (0.42) | PAK1TRPV1GAANR2E1MAPK10 | |
| SCHEMBL2382772 | 0.76 | TRPV1 (0.49) | TRPV1KITNR2E1MAPK10 | |
| SCHEMBL2385069 | 0.76 | PAK1 (0.40) | PAK1TRPV1NR2E1MAPK10CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1608373-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083235-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | CCR2 369/4885KCNH2 2585/4885PAK1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.